The Biotechnology Large & Mid cap stocks segment on TrackInsight has bounced by 3,83% on Monday, May 12th, bringing the year-to-date cumulative performance of the 11 ETFs included in this segment above 10%. Most of them are exposed to US-listed companies that are part of the NASDAQ Biotechnology Index. The hope that pharmaceutical companies might find a way to fight off the coronavirus triggered a wave of optimism amongst investors. Even if Biotechnology ETFs have been in the spotlight these last weeks, flows have remained quiet on the primary market where recent inflows have offset the few withdrawals recorded at the worst of the crisis in March. In 2020, this segment benefits from inflows of $ 415 million which positively contributed to the current assets under management level of $ 11,7 Bn.